Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer.
Published: 9th August 2017
Authors: S. D. Nelen, M. van Putten, V. E. P. P. Lemmens, K. Bosscha, J. H. W. de Wilt, R. H. A. Verhoeven et al.
This study assessed trends in the treatment and survival of palliatively treated patients with gastric cancer, with a focus on age‐related differences.
For this retrospective, population‐based, nationwide cohort study, all patients diagnosed between 1989 and 2013 with non‐cardia gastric cancer with metastasized disease or invasion into adjacent structures were selected from the Netherlands Cancer Registry. Trends in treatment and 2‐year overall survival were analysed and compared between younger (age less than 70 years) and older (aged 70 years or more) patients. Analyses were done for five consecutive periods of 5 years, from 1989–1993 to 2009–2013. Multivariable logistic regression analysis was used to examine the probability of undergoing surgery. Multivariable Cox regression analysis was used to identify independent risk factors for death.
Palliative resection rates decreased significantly in both younger and older patients, from 24·5 and 26·2 per cent to 3·0 and 5·0 per cent respectively. Compared with patients who received chemotherapy alone, both younger (21·6
Despite changes in the use of resection and chemotherapy as palliative treatment, overall survival rates of patients with advanced and metastatic gastric cancer did not improve.Read more
You may also be interested in
Authors: D. W. Kjaer, H. Larsson, L. B. Svendsen, L. S. Jensen
Notes: Better short term outcome
Randomized clinical trial
Randomized clinical trial of psychological support and sleep adjuvant measures for postoperative sleep disturbance in patients undergoing oesophagectomy.
Authors: M. Scarpa, E. Pinto, E. Saraceni, F. Cavallin, M. Parotto, R. Alfieri et al.
Notes: Psychologists improve postoperative sleep
Adaptation of the By‐Band randomized clinical trial to By‐Band‐Sleeve to include a new intervention and maintain relevance of the study to practice. BJS 2017; 104: 1207-1214.
Authors: C. A. Rogers, B. C. Reeves, J. Byrne, J. L. Donovan, G. Mazza, S. Paramasivan et al.
Notes: Something to consider
Loss of SRY‐box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.
Authors: F. J. C. ten Kate, S. H. van Olphen, M. J. Bruno, B. P. L. Wijnhoven, J. J. B. van Lanschot, L. H. J. Looijenga et al.
Notes: Useful biomarker especially for early disease
Authors: J. Thereaux, T. Lesuffleur, M. Païta, S. Czernichow, A. Basdevant, S. Msika et al.
Notes: Poor follow up despite international guidelines
Meta‐analysis of health‐related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer. BJS 2017; 104: 1131-1140.
Authors: J. H. Kauppila, S. Xie, A. Johar, S. R. Markar, P. Lagergren
Notes: Only different in short term
Authors: C. Lin, H. Liu, H. Zhang, Y. Cao, R. Li, S. Wu et al.
Notes: Tumour microenvironment is important
Corrigendum: Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. BJS 2017; 104: 947-947.
Authors: J. M. Findlay, K. M. Bradley, L. M. Wang, J. M. Franklin, E. J. Teoh, F. V. Gleeson et al.
Preoperative imaging and prediction of oesophageal conduit necrosis after oesophagectomy for cancer. BJS 2017; 104: 1346-1354.
Authors: P. Lainas, D. Fuks, S. Gaujoux, Z. Machroub, A. Fregeville, T. Perniceni et al.
Notes: Vascular abnormalities may be causal
Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer. BJS 2017; 104: 1235-1243.
Authors: M. Bencivenga, G. Verlato, D.‐S. Han, D. Marrelli, F. Roviello, H.‐K. Yang et al.
Notes: Good performance
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. BJS 2017; 104: 1226-1234.
Authors: Z.‐X. Wang, G.‐X. Li, Z.‐W. Zhou, Z.‐P. Huang, F. Wang, R.‐H. Xu et al.
Notes: Facilitates individualized treatment